

Program and Speakers

7:00 — 7:30 am Breakfast and Exhibits

7:30 — 7:40 am Welcome and Opening Remarks

Adrienne Graves, PhD and
Andrew G. Iwach, MD

7:40 — 8:00 am Opening Keynote Address

Louis Cantor, MD, “State of Glaucoma Therapy 2013: Is 13 our lucky number?”
Chairman and Professor of Ophthalmology, Indiana University

8:00 — 9:10 am New Horizons in Glaucoma Devices

Speaker/Moderator: **Ike Ahmed, MD, FRCSC**, “The Future of Glaucoma Surgery”
Assistant Professor, Faculty of Medicine, University of Toronto

Participants:

- AqueSys, Inc.—**Ron Bache**, President and CEO
- Glaukos Corporation—**Mike Neilon, MBA**, VP, International
- InnFocus, Inc.—**Leonard Pinchuk, PhD, D.Sc.**, President and CEO
- Ivantis, Inc.—**Brett Trauthen**, Chief Scientific Officer
- Sensimed, AG—**Jean-Marc Wismer, MScEE, MBA**, CEO
- Transcend Medical—**Sean Ianchulev, MD, MPH**, Chief Medical Officer

Q & A

9:10 — 9:50 am Industry Panel Discussion: Glaucoma Devices

Moderators: **Alan S. Crandall, MD**, Sr. Vice Chairman of Ophthalmology & Visual Sciences,
John A. Moran Eye Center

H. Dunbar Hoskins, Jr., MD, former EVP American Academy of Ophthalmology and Co-founder,
Glaucoma Research Foundation

Panelists:

- Carl Zeiss Meditec, **Ralf Kuschnerit, PhD, MBA**, President and CEO
- Abbott Medical Optics, **Jane E. Rady**, Divisional VP, Business Development
- Alcon Laboratories, Inc., **Greg Kunst, MBA**, Global Marketing Director, Surgical Glaucoma
- Lumenis Ltd., **Kfir Azoulay**, VP and General Manager, Ophthalmology Business Unit

9:50 — 10:15 am Morning Break, Exhibits and Networking Opportunity

10:15 — 10:35 am Glaucoma Research Foundation Update

Introduction: **Thomas M. Brunner**, President and CEO, Glaucoma Research Foundation

Speaker: **Jeffrey Goldberg, MD, PhD**, “Why Glaucoma Biomarkers?”
Professor of Ophthalmology, Shiley Eye Center, University of California, San Diego

10:35 — 11:50 am New Horizons in Glaucoma Drug Delivery

Moderators: **Eugene de Juan, Jr., MD**, Founder and Vice-Chairman, ForSight Labs

Eliot Lazar, MD, President, eICON Medical

Participants:

- Amorphex Therapeutics LLC—**Robert F. Thompson**, President and CEO
- Clearside Biomedical, Inc.—**Daniel White**, CEO and President
- Euclid Systems Corporation—**Dale P. DeVore, PhD**, Chief Scientific Officer
- Icon Bioscience, Inc.—**William S. White**, CEO and President
- Liquidia Technologies, Inc.—**Benjamin Yerxa, PhD**, Chief Scientific Officer
- Ocular Therapeutix, Inc.—**Amar Sawhney, PhD**, President and CEO
- Mobius Therapeutics, LLC—**Ed Timm**, President and CEO

Q & A

11:50 — 12:10 pm Navigating New Horizons: Driving Discovery to Clinical Success

Anthony P. Adamis, MD, VP, Global Head of Ophthalmology, Genentech, Inc.

Interviewed by:

Emmett Cunningham, Jr., MD, PhD, MPH, Partner, Clarus Ventures

12:10 — 1 pm Luncheon

Program and Speakers

1:00 — 1:45 pm

Moderators:

Participants:

New Horizons in Glaucoma Pharmaceuticals (I)

Stuart B. Abelson, MBA, President and CEO, Ora, Inc.

L. Jay Katz, MD, Director, Glaucoma Service, Wills Eye Institute

- Acorn Biomedical, Inc.—**Alan J. Jacobs, MD, PhD**, President and CEO
 - Ono Pharma USA, Inc.—**Douglas T. Ross, PhD**, Senior Director, Drug Development
 - Quark Pharmaceuticals Inc.—**Daniel Zurr, PhD**, Chairman and CEO
- Q & A

1:45 — 2:30 pm

Moderators:

Participants:

New Horizons in Glaucoma Pharmaceuticals (II)—Out Flow Drugs

Gary D. Novack, PhD, “A Brief Historical Perspective and Opportunities”

President, Pharmalogic Development, Inc.

Barbara Wirostko, MD, “Real-life challenges in developing outflow drugs”

Clinical Adjunct Associate Professor, Moran Eye Center

- Amakem Therapeutics—**Jack Elands, PhD**, CEO
 - Aerie Pharmaceuticals, Inc.—**Thomas J. van Haarlem, MD**, President and CEO
 - Inotek Pharmaceuticals—**Paul G. Howes**, President and CEO
- Q & A

2:30 — 3:10 pm

Moderators:

Panelists:

Industry Panel Discussion: Glaucoma Pharmaceuticals

Kuldev Singh, MD, MPH, Professor of Ophthalmology, Stanford University Medical Center

K. Angela Macfarlane, JD, President and CEO, ForSight Labs

Alcon Laboratories, Inc., **Robert Y. Kim, MD**, VP & Head, Pharmaceutical Product Development

- Allergan, Inc., **Rhett M. Schiffman, MD, MS, MHSA**, VP of Global Drug Development and Therapeutic Area Head of Ophthalmology
- Bausch + Lomb, **Tracy M. Valorie BS, MBA**, Global Head of Glaucoma
- Genentech, Inc., **Phillip C. Lai, MD**, Associate Medical Director
- Merck & Co., Inc., **John W. Grunden, PharmD**, Regional Director of Medical Affairs

3:10 — 3:35 pm

Afternoon Break, Exhibits and Networking Opportunity

3:35 — 4:15 pm

Moderators:

Panelists:

Advancing New Horizons: Focusing on Collaboration and Public Private Partnerships

M. Roy Wilson, MD, MS, Deputy Director, Strategic Scientific Planning and Program Coordination, National Institute on Minority Health and Health Disparities

Anne L. Coleman, MD, PhD, Professor of Ophthalmology, Jules Stein Eye Institute

Frank L. Douglas, PhD, MD, Advisory Council, National Center for Advancing Translational Sciences (NCATS)

Debra R. Lappin, JD, President, Council for American Medical Innovation

Q & A

4:15 — 4:45 pm

Moderators:

Panelists:

FDA: Getting to New Horizons

Paul Chaney, President and CEO, PanOptica, Inc.

Eve Higginbotham, SM, MD, Visiting Scholar in Health Equity, Association of American Medical Colleges, Co-Founder and Director, ROI Squared LLC

Wiley A. Chambers, MD, Deputy Director, (Transplant and Ophthalmology), Center for Drug Evaluation and Research, FDA

Judy F. Gordon, DVM, Founder, ClinReg Consulting Services, Inc.

Sean Ianchulev, MD, MPH, Chief Medical Officer, Transcend Medical

Q & A

4:45 — 5:25 pm

Moderator:

Panelists:

Funding New Horizons: Venture Capital Panel Discussion

William J. Link, PhD, Managing Director, Versant Ventures

Wende Hutton, General Partner, Canaan Partners

Gil Kliman, MD, Managing Director, InterWest Partners

J. Casey McGlynn, JD, Partner, Wilson Sonsini Goodrich & Rosati

Anand Mehra, MD, Partner, Sofinnova Ventures

Q & A

5:25 — 5:30 pm

Closing Remarks—Drs. Graves and Iwach

5:30 — 7:00 pm

Reception, Exhibits and Networking